Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072584927> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2072584927 endingPage "357" @default.
- W2072584927 startingPage "351" @default.
- W2072584927 abstract "Cystic fibrosis (CF) is an autosomal recessive disorder that is caused by over 850 different mutations in the CF gene. It is useful to group these mutations according to the defect that results in the CFTR mRNA or protein. New pharmacological treatments targeted towards specific mutations that are relatively common are being developed. Class I mutations do not produce CFTR protein because of a premature stop signal in the CFTR DNA. These null mutations can be corrected by certain aminoglycosides which cause the aberrant stop signal to be skipped. Mutations leading to a CFTR protein that attains an unstable structure shortly after translation in the endoplasmic reticulum form class II. Class II mutations can be restored to the protein trafficking pathway by manipulation of chaperone protein/CFTR interactions with chemical chaperones or drugs that affect gene regulation such as the butyrates. Production of a CFTR with reduced Cl(-) transport on the basis of abnormal regulation of the chloride channel is the basis of class III. Genistein can overcome this block in regulation. Mutations that partially reduce chloride conductance through CFTR (class IV) can be stimulated with milrinone, which is a phosphodiesterase inhibitor. Finally, mutations that lead to a severe reduction in normal CFTR protein form class V. Increased levels of CFTR could be generated with the butyrates or supplemented with gene therapy. Although most of the reported mutations in CFTR are rare and unclassified, it may be possible to use genotype-phenotype correlations to determine the best approach." @default.
- W2072584927 created "2016-06-24" @default.
- W2072584927 creator A5014418025 @default.
- W2072584927 date "2000-01-01" @default.
- W2072584927 modified "2023-10-16" @default.
- W2072584927 title "Future Pharmacological Treatment of Cystic Fibrosis" @default.
- W2072584927 cites W185124257 @default.
- W2072584927 cites W1975971473 @default.
- W2072584927 cites W1977946638 @default.
- W2072584927 cites W1988106177 @default.
- W2072584927 cites W1990991203 @default.
- W2072584927 cites W1999690639 @default.
- W2072584927 cites W2014319545 @default.
- W2072584927 cites W2030955600 @default.
- W2072584927 cites W2032258216 @default.
- W2072584927 cites W2035026471 @default.
- W2072584927 cites W2038701031 @default.
- W2072584927 cites W2043502964 @default.
- W2072584927 cites W2058757351 @default.
- W2072584927 cites W2062364311 @default.
- W2072584927 cites W2082968284 @default.
- W2072584927 cites W2117143712 @default.
- W2072584927 cites W2139398847 @default.
- W2072584927 doi "https://doi.org/10.1159/000029528" @default.
- W2072584927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10940786" @default.
- W2072584927 hasPublicationYear "2000" @default.
- W2072584927 type Work @default.
- W2072584927 sameAs 2072584927 @default.
- W2072584927 citedByCount "38" @default.
- W2072584927 countsByYear W20725849272012 @default.
- W2072584927 countsByYear W20725849272016 @default.
- W2072584927 countsByYear W20725849272017 @default.
- W2072584927 countsByYear W20725849272018 @default.
- W2072584927 crossrefType "journal-article" @default.
- W2072584927 hasAuthorship W2072584927A5014418025 @default.
- W2072584927 hasConcept C104317684 @default.
- W2072584927 hasConcept C127716648 @default.
- W2072584927 hasConcept C145822097 @default.
- W2072584927 hasConcept C153911025 @default.
- W2072584927 hasConcept C158617107 @default.
- W2072584927 hasConcept C2776938444 @default.
- W2072584927 hasConcept C2778428886 @default.
- W2072584927 hasConcept C501734568 @default.
- W2072584927 hasConcept C54355233 @default.
- W2072584927 hasConcept C62478195 @default.
- W2072584927 hasConcept C71924100 @default.
- W2072584927 hasConcept C86803240 @default.
- W2072584927 hasConcept C95444343 @default.
- W2072584927 hasConceptScore W2072584927C104317684 @default.
- W2072584927 hasConceptScore W2072584927C127716648 @default.
- W2072584927 hasConceptScore W2072584927C145822097 @default.
- W2072584927 hasConceptScore W2072584927C153911025 @default.
- W2072584927 hasConceptScore W2072584927C158617107 @default.
- W2072584927 hasConceptScore W2072584927C2776938444 @default.
- W2072584927 hasConceptScore W2072584927C2778428886 @default.
- W2072584927 hasConceptScore W2072584927C501734568 @default.
- W2072584927 hasConceptScore W2072584927C54355233 @default.
- W2072584927 hasConceptScore W2072584927C62478195 @default.
- W2072584927 hasConceptScore W2072584927C71924100 @default.
- W2072584927 hasConceptScore W2072584927C86803240 @default.
- W2072584927 hasConceptScore W2072584927C95444343 @default.
- W2072584927 hasIssue "4" @default.
- W2072584927 hasLocation W20725849271 @default.
- W2072584927 hasLocation W20725849272 @default.
- W2072584927 hasOpenAccess W2072584927 @default.
- W2072584927 hasPrimaryLocation W20725849271 @default.
- W2072584927 hasRelatedWork W1968164965 @default.
- W2072584927 hasRelatedWork W1977188111 @default.
- W2072584927 hasRelatedWork W2015531712 @default.
- W2072584927 hasRelatedWork W2035177679 @default.
- W2072584927 hasRelatedWork W2113074631 @default.
- W2072584927 hasRelatedWork W2117143712 @default.
- W2072584927 hasRelatedWork W2164659357 @default.
- W2072584927 hasRelatedWork W2366353213 @default.
- W2072584927 hasRelatedWork W2367070451 @default.
- W2072584927 hasRelatedWork W2041984778 @default.
- W2072584927 hasVolume "67" @default.
- W2072584927 isParatext "false" @default.
- W2072584927 isRetracted "false" @default.
- W2072584927 magId "2072584927" @default.
- W2072584927 workType "article" @default.